Literature DB >> 20857187

Neurocognitive impairment and medication adherence in HIV patients with and without cocaine dependence.

Christina S Meade1, Nina A Conn, Linda M Skalski, Steven A Safren.   

Abstract

Cocaine abuse among HIV patients is associated with faster disease progression and mortality. This study examined the relationship between neurocognitive functioning and medication adherence in HIV patients with (n = 25) and without (n = 39) current cocaine dependence. Active users had greater neurocognitive impairment (mean T-score = 35.16 vs. 40.97, p < .05) and worse medication adherence (mean z-score = -0.44 vs. 0.27, p < .001). In a multiple regression model, neurocognitive functioning (β = .33, p < .01) and cocaine dependence (β = -.36, p < .01) were predictive of poorer adherence. There was a significant indirect effect of cocaine dependence on medication adherence through neurocognitive impairment (estimate = -0.15, p < .05), suggesting that neurocognitive impairment partially mediated the relationship between cocaine dependence and poorer adherence. These results confirm that cocaine users are at high risk for poor HIV outcomes and underscore the importance of treating both neurocognitive impairment and cocaine dependence among HIV patients.

Entities:  

Mesh:

Year:  2010        PMID: 20857187      PMCID: PMC3049963          DOI: 10.1007/s10865-010-9293-5

Source DB:  PubMed          Journal:  J Behav Med        ISSN: 0160-7715


  81 in total

1.  Dose-related neurobehavioral effects of chronic cocaine use.

Authors:  K I Bolla; R Rothman; J L Cadet
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1999       Impact factor: 2.198

2.  Personality profile and neuropsychological test performance in chronic cocaine-abusers.

Authors:  M Rosselli; A Ardila; M Lubomski; S Murray; K King
Journal:  Int J Neurosci       Date:  2001-09       Impact factor: 2.292

3.  Optimal recall period and response task for self-reported HIV medication adherence.

Authors:  Minyi Lu; Steven A Safren; Paul R Skolnik; William H Rogers; William Coady; Helene Hardy; Ira B Wilson
Journal:  AIDS Behav       Date:  2007-06-19

4.  HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%.

Authors:  Jonathan Shuter; Julie A Sarlo; Tina J Kanmaz; Richard A Rode; Barry S Zingman
Journal:  J Acquir Immune Defic Syndr       Date:  2007-05-01       Impact factor: 3.731

Review 5.  The relationship between neuropsychological functioning and HAART adherence in HIV-positive adults: a systematic review.

Authors:  Travis I Lovejoy; Julie A Suhr
Journal:  J Behav Med       Date:  2009-03-17

6.  Numeracy skills explain racial differences in HIV medication management.

Authors:  Drenna Waldrop-Valverde; Chandra Y Osborn; Allan Rodriguez; Russell L Rothman; Mahendra Kumar; Deborah L Jones
Journal:  AIDS Behav       Date:  2009-08-08

7.  Memory functioning in polysubstance dependent women.

Authors:  Krista Lisdahl Medina; Paula K Shear; John Schafer
Journal:  Drug Alcohol Depend       Date:  2006-04-03       Impact factor: 4.492

8.  Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors.

Authors:  Valerio Tozzi; Pietro Balestra; Rita Bellagamba; Angela Corpolongo; Maria Flora Salvatori; Ubaldo Visco-Comandini; Chrysoula Vlassi; Marinella Giulianelli; Simonetta Galgani; Andrea Antinori; Pasquale Narciso
Journal:  J Acquir Immune Defic Syndr       Date:  2007-06-01       Impact factor: 3.731

9.  Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study.

Authors:  Giovanni Schifitto; Bradford A Navia; Constantin T Yiannoutsos; Christina M Marra; Linda Chang; Thomas Ernst; Jeffrey G Jarvik; Eric N Miller; Elyse J Singer; Ronald J Ellis; Dennis L Kolson; David Simpson; Avindra Nath; Joseph Berger; Sharon L Shriver; Linda L Millar; Dodi Colquhoun; Robert Lenkinski; R Gilberto Gonzalez; Stuart A Lipton
Journal:  AIDS       Date:  2007-09-12       Impact factor: 4.177

10.  The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.

Authors:  Perrine Roux; M Patrizia Carrieri; Virgine Villes; Pierre Dellamonica; Isabelle Poizot-Martin; Isabelle Ravaux; Bruno Spire
Journal:  Addiction       Date:  2008-09-04       Impact factor: 6.526

View more
  57 in total

Review 1.  Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate.

Authors:  Colin N Haile; James J Mahoney; Thomas F Newton; Richard De La Garza
Journal:  Pharmacol Ther       Date:  2012-01-31       Impact factor: 12.310

2.  Psychosocial Correlates of Medication Adherence among HIV-Positive, Cognitively Impaired Individuals.

Authors:  Timothy J Arentsen; Stella Panos; April D Thames; J Natalie Arbid; Steven A Castellon; Charles H Hinkin
Journal:  J HIV AIDS Soc Serv       Date:  2016-09-23

3.  Substance Abuse, Hepatitis C, and Aging in HIV: Common Cofactors that Contribute to Neurobehavioral Disturbances.

Authors:  Randi Melissa Schuster; Raul Gonzalez
Journal:  Neurobehav HIV Med       Date:  2012-02-16

4.  Individualized texting for adherence building (iTAB) for methamphetamine users living with HIV: A pilot randomized clinical trial.

Authors:  David J Moore; Elizabeth C Pasipanodya; Anya Umlauf; Alexandra S Rooney; Ben Gouaux; Colin A Depp; J Hampton Atkinson; Jessica L Montoya
Journal:  Drug Alcohol Depend       Date:  2018-06-21       Impact factor: 4.492

5.  Applying behavioral activation to sustain and enhance the effects of contingency management for reducing stimulant use among individuals with HIV infection.

Authors:  Matthew J Mimiaga; Elizabeth F Closson; David W Pantalone; Steven A Safren; Jennifer A Mitty
Journal:  Psychol Health Med       Date:  2018-09-13       Impact factor: 2.423

6.  Modeling a Theory-Based Approach to Examine the Influence of Neurocognitive Impairment on HIV Risk Reduction Behaviors Among Drug Users in Treatment.

Authors:  Tania B Huedo-Medina; Roman Shrestha; Michael Copenhaver
Journal:  AIDS Behav       Date:  2016-08

7.  Crack cocaine use impairs anterior cingulate and prefrontal cortex function in women with HIV infection.

Authors:  Vanessa J Meyer; Deborah M Little; Daniel A Fitzgerald; Erin E Sundermann; Leah H Rubin; Eileen M Martin; Kathleen M Weber; Mardge H Cohen; Pauline M Maki
Journal:  J Neurovirol       Date:  2014-04-24       Impact factor: 2.643

Review 8.  Substance use: impact on adherence and HIV medical treatment.

Authors:  Adam Gonzalez; Jennifer Barinas; Conall O'Cleirigh
Journal:  Curr HIV/AIDS Rep       Date:  2011-12       Impact factor: 5.071

9.  Perspectives of middle-aged African-American women in the Deep South on antiretroviral therapy adherence.

Authors:  Margaret DeMoss; Loida Bonney; Jennifer Grant; Robin Klein; Carlos del Rio; Judith C Barker
Journal:  AIDS Care       Date:  2013-10-08

Review 10.  Drug induced increases in CNS dopamine alter monocyte, macrophage and T cell functions: implications for HAND.

Authors:  Peter J Gaskill; Tina M Calderon; Jacqueline S Coley; Joan W Berman
Journal:  J Neuroimmune Pharmacol       Date:  2013-03-01       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.